Phenobarbital for neonatal seizures:response rate and predictors of refractoriness by Spagnoli, Carlotta et al.
1 
 
Title page 
Original article 
Phenobarbital for neonatal seizures: response rate and refractoriness predictors 
Carlotta SPAGNOLI, MD
1*
, Stefano SERI, MD
2, 3
, Elena PAVLIDIS, MD
1
, Silvia MAZZOTTA, 
MD
1
, Annalisa PELOSI, PsyD
4
, Francesco PISANI, MD
1  
1  
Child Neuropsychiatry Unit, Neuroscience Department, University of Parma, Parma, Italy
 
2  
Department of Clinical Neurophysiology, The Birmingham Children's Hospital NHS Foundation 
Trust, Birmingham, UK 
 
3
Aston Brain Centre, School of Life and Health Sciences, Aston University, Birmingham, UK
 
4 
Psychology Unit, Neuroscience Department, University of Parma, Parma, Italy
 
* 
Corresponding author: Carlotta Spagnoli,  
Postal address: Department of Neuroscience, University of Parma, Via A. Gramsci 14, 43126 
Parma, Italy. E-mail address: carlotta.spagnoli@gmail.com. Phone number: 39-0521-702205. 
Fax number: 39-0521-704708. 
Other Authors' e-mail addresses: 
Stefano Seri: s.seri@aston.ac.uk, Elena Pavlidis: elena.pavlidis2@gmail.com, Silvia Mazzotta: 
mazzotta.silvia@gmail.com, Annalisa Pelosi: annalisa.pelosi@unipr.it, Francesco Pisani: 
francesco.pisani@unipr.it 
Conflicts of Interest and Source of Funding: none to declare. 
Running title: Phenobarbital in neonatal seizures. 
Page 1
2 
 
Word count: 2588 (main manuscript), 246 (abstract); number of references: 36; number of tables: 2; 
number of figures: 4; number of supplemental figures/tables/references: 0. 
Page 2
3 
 
Abstract 
Background: Phenobarbital is the first-line choice for neonatal seizures treatment, despite a response 
rate of approximately 45%. Failure to respond to acute anticonvulsants is associated with poor 
neurodevelopmental outcome but knowledge on predictors of refractoriness is limited.  
Objectives: To quantify response rate to phenobarbital and to establish variables predictive of its 
lack of efficacy. 
Methods: We retrospectively evaluated newborns with electrographically-confirmed neonatal 
seizures admitted between January 1999 and December 2012 to the Neonatal Intensive Care Unit of 
Parma University-Hospital (Italy), excluding neonates with status epilepticus. Response was 
categorized as complete (cessation of clinical and electrographic seizures after phenobarbital 
administration), partial (reduction but not cessation of electrographic seizures with the first bolus, 
response to the second bolus) or absent (no response after the second bolus). Multivariate analysis 
was used to identify independent predictors of refractoriness. 
Results: Out of 91 newborns receiving phenobarbital, 57 (62.6%) responded completely, 15 (16.5%) 
partially and 19 (20.9%) did not respond.  Seizure type (p=.02), background EEG (p≤.005) and 
neurological examination (p≤.005) correlated with response to phenobarbital. However EEG 
(p≤.02) and seizure type (p≤.001) were the only independent predictors. 
Conclusions: Our results suggest a prominent role of neurophysiological variables (background 
EEG and electrographic-only seizure type) in predicting the absence of response to phenobarbital in 
high risk newborns.  
Key words: neonatal seizures, therapy, phenobarbital, treatment outcome, refractoriness predictors, 
newborns. 
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Background 
The presence of neonatal seizures (NS) is associated with increased likelihood of negative outcome, 
including death and long-term neurodevelopmental sequelae.
1
 
Therapeutic options are still unsatisfactory,
2
 as phenobarbital (still to be regarded as the the first line 
drug) has been reported to control NS in up to 43% of cases
3 
and the use of second-generation 
anticonvulsant drugs is still limited due to the paucity of available evidence,
4
 in spite of the 
significant effort in developing alternative or adjunct therapeutic strategies
5
 that could improve 
response rates, in an attempt to improve neurodevelopmental outcome. 
Various studies reported refractoriness to acute administration of antiepileptic drugs in the neonatal 
period to be predictive of adverse outcome
3, 6, 7
 and of subsequent development of chronic 
epilepsy.
8, 9
 While there has been growing interest in the definition of predictors of medical 
intractability in pediatric epilepsy,
10
 factors allowing the prediction of failure to control neonatal 
seizures remain largely elusive. 
To contribute to the understanding of predictors of refractoriness to acute phenobarbital treatment in 
NS, we reviewed the charts of patients seen at the Neonatal Intensive Care Unit (NICU) of our 
institution to quantify the percentage of newborns with electrographically-confirmed NS who failed 
to respond to phenobarbital to identify early clinical and instrumental findings predictive of 
refractoriness.  
 
Materials and methods 
We retrospectively reviewed clinical and instrumental data regarding newborns with 
electrographically-confirmed NS, consecutively admitted to the NICU at Parma University-Hospital 
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between January 1999 and December 2012 (Figure 1). Both electroclinical and electrographic-only 
seizures were included. We excluded newborns with a diagnosis of neonatal status epilepticus. All 
newborns at high risk for NS due to the presence of predisposing factors such as hypoxic-ischemic 
encephalopathy, sepsis, meningitis, metabolic disorders, brain malformations, intraventricular 
hemorrhage (IVH) or periventricular leukomalacia (PVL) on brain US scans, or with clinical signs 
suggestive of seizures, underwent serial EEGs during the neonatal period. Conventional polygraphic 
video-EEGs in our NICU were recorded by specialised personnel during day shifts from Monday to 
Friday, while on nights and during week-ends EEGs can be requested if urgent, but recordings are 
not undertaken on a regular basis. They were recorded at the bedside and, depending on infants’ 
head size, 21 or 10 cerebral electrodes were applied according to the 10-20 International System 
modified for neonates. Electrocardiogram, lateral eye movements, chin electromyographic activity, 
and abdominal respiration were additional physiologic variables most frequently monitored. 
Recordings continued until a complete cycle of wakefulness, quiet and active sleep were obtained, 
or, if not clearly distinguishable, they continued for at least 60 minutes.  
NS were defined according to electroencephalographic (EEG) criteria as ictal discharges showing a 
clear onset and termination, duration of at least 10 seconds and an evolution in frequency and 
morphology over time.
11
 We collected the following clinical data: gender, gestational age, mode of 
delivery (spontaneous versus caesarean section), birth weight, Apgar scores at 1, 5 and 10 minutes, 
etiology, time of seizure onset (<48 hours of life or afterwards), seizure type, ultrasound brain scans, 
background EEG findings and neurological examination. These variables were scored as previously 
reported.
1
 Background EEG findings were grouped into two categories: 1) normal or mildly 
abnormal in the presence of excess sharp activity, absence or decreased frequency of normal 
patterns, excessively long low voltage periods, or overall slightly decreased voltage; and 2) 
moderately or severely abnormal when there were asymmetries in voltage or frequencies, 
asynchrony for age, isoelectric or low voltage invariant activity, burst suppression pattern, or 
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permanent discontinuous activity.12 The first EEG in which electroclinical and/or electrographic-
only seizures were recorded was used to score background activity. 
Newborns were followed up with serial cranial ultrasound scans with a 7 MHz probe (Acuson 
Aspen). Intraventricular haemorrhage, if present, was scored according to Papile's classification,
13
 
whereas ischaemic lesions according to deVries
14
 and ventriculomegaly according to Levene.
15
 
Ultrasound findings were grouped into three categories: normal; mildly abnormal: intraventricular 
hemorrhage (IVH) of degrees 1 or 2, transient periventricular echodensities or borderline ventricular 
dilatation; severely abnormal:  IVH of degree 3 or 4, intraparenchymal hemorrhage, periventricular 
leukomalacia, and brain malformations. NS were classified as subtle, clonic (multifocal/focal), tonic 
(generalized, focal), and myoclonic (focal, multifocal, generalized)
16
 and had to be associated with 
EEG changes. However, for statistical purposes, seizure types were divided as: 1) one electroclinical 
seizure type, 2) more than one electroclinical seizure type, 3) electrographic-only seizures. To avoid 
the inclusion of paroxysmal non-epileptic neonatal movements
17
 we selected only 
electrographically-confirmed NS. The neurological examination performed before the onset of 
neonatal seizures was classified as follows: (i) normal/,mildly abnormal: with normal muscle tone 
or mild hypertonia, active muscle movements present, normal alertness for age or hyperexcitability; 
(ii) moderately abnormal: with hypotonia/hypertonia, decreased active muscle movements, and 
lethargy; and (iii) severely abnormal: flaccid, inactive, and/or coma.  
We excluded newborns with neonatal status epilepticus (NSE) defined as continuous seizure activity 
for at least 30 minutes or recurrent seizures lasting a total of ≥30 minutes without definite return to 
the baseline neurological condition between seizures, in any 1-hour period (hourly seizure burden 
range: ≥50% - 100%).
18 
Newborns with NSE were excluded from this retrospective study due to its 
intrinsic refractoriness to phenobarbital. Etiologies were grouped in the following 3 categories: 
hypoxic-ischemic encephalopathy, cerebral hemorrhage and other etiologies. Perinatal asphyxia was 
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defined based on the presence of an Apgar score ≤5 at 5 minutes, need for resuscitation with 
positive pressure ventilation and oxygen for >1 minute immediately after birth, an arterial pH ≤7.10 
and a base deficit ≥14 mmol/L within the first hour after birth.
19
 Hypoxic-ischaemic encephalopathy 
was defined and scored according to Sarnat and Sarnat.
20
 Within the group labeled as “other 
etiologies” we included cases of cerebral malformation, inherited metabolic disorder, transient 
metabolic disorder (e.g. hypocalcemia, hypoglycemia, uremia), central nervous system 
infection/sepsis and unknown etiology. 
Ethics, consent and permissions 
Informed consent to use of patients’ clinical data for research purpose was obtained from parents in 
accordance with ethics policy of our Institution, which approved the study. Written informed 
consent forms were stored in each patient’s hospital chart. 
Treatment protocol for NS in our Unit 
The therapeutic protocol used in our Unit during study period was as follows: intravenous (IV) 
bolus of phenobarbital at a dose of 20 mg/kg, repeated once if seizures persist 15 minutes after 
bolus has been completed, followed by IV administration of phenytoin at a loading dose of 20 
mg/kg at a rate of no more than 1 mg/kg/minute for persisting seizures. If seizures persisted in spite 
of this treatment, our third-line anticonvulsant was an IV bolus of midazolam at 0.15 mg/kg 
followed by continuous IV infusion at 1 µg/kg/minute, increased by 1 µg/kg/minute every 15 
minutes.
1
 In some instances, IV diazepam was administered as either the second or third-line choice, 
at a dose of 0.2-0.5 mg/kg. However, the neonatologists in charge decided the therapy according to 
the clinical context (Figure 2).   
Response to phenobarbital therapy classification.  
Page 7
8 
We classified patients’ response to phenobarbital administration as follows: 0= complete response to 
the first phenobarbital bolus; 1= partial response, corresponding to reduction but not cessation of 
electrographic seizures with the first bolus and response to the second bolus, 2= no seizure 
reduction with the second bolus of phenobarbital. 
Statistical analysis 
Nominal data were analyzed by means of the χ2 test or Fisher’s exact test as appropriate.  
Odds ratio (OR) was calculated using a univariate logistic regression model to determine which 
independent variable(s) were related to refractoriness to phenobarbital. Variables with a p value 
<0.05 and with an OR>1 on univariate analysis were accepted as significant and included in a 
multiple logistic regression analysis used to evaluate which independent variable/s were related to 
failure to respond to phenobarbital. 
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS 
Version 21; IBM SPSS Statistics for Windows, Armonk, NY, 2012). 
 
Results 
From the total cohort of 154 newborns who had electrographically-confirmed NS, we excluded 47 
cases with NSE (28 full-term and 19 preterm neonates), thus identifying 107 newborns, of whom 50 
were born at term and 57 were preterm neonates. Sixteen patients did not receive phenobarbital 
(16/107=15%), 11 of which were born preterm. Four neonates exclusively received an etiological 
therapy: one full-term was administered pyridoxine and one calcium, whereas two preterm neonates 
received IV glucose. 
The remaining 91 newborns (55 males), 45 (49.5%) born at term and 46 (50.5%) preterm were 
included in the analysis. Detailed patients’ characteristics are shown in Table 1.  
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Seizure semiology: a total of five newborns had exclusively electrographic seizures. Two showed a 
complete response and three a partial response to phenobarbital. Seizure semiology in newborns 
with electroclinical seizures is depicted in Figure 3. Data are divided according to the number of 
different seizure types presented by each newborn in: one seizure type and more than one seizure 
type. In this second group, if clonic seizures were present, then the newborn was classified as 
presenting with clonic seizures, while when different seizure types were present, we classified 
patients according to their prevailing seizure type into: myoclonic, tonic, or subtle. 
Etiologies in our cohort were distributed as follows: 45 patients had hypoxic-ischemic 
encephalopathy (29 showed a complete response to phenobarbital, 9 a partial response, 7 no 
response); 21 had a cerebral hemorrhage (14 showed a complete response to phenobarbital, 2 a 
partial response, 5 no response); 25 had other etiologies: 4 had a cerebral malformation, 3 an 
inherited metabolic disorder, 9 had a transient metabolic disorder, 4 had a central nervous system 
infection/sepsis, one had a syndromic diagnosis, in 4 this was unknown. Of these, 14 showed a 
complete response to phenobarbital, 4 a partial response, 7 no response. The distribution of response 
categories did not significantly differ according to etiology (p=0.653). 
The number of newborns receiving only phenobarbital was 34 among full—term newborns 
(34/50=68%) and 40 (40/57= 70.2%) among preterm newborns. 
Response to phenobarbital 
Of the 91 newborns being treated with phenobarbital, 57 showed a complete response (62.6%), 15 
(16.5%) a partial response and 19 (20.9%) no response.  
Among examined variables, seizure type (p=.02), background EEG (p≤.005) and neurological 
examination (p≤.005) correlated with response to phenobarbital. The multiple logistic regression 
analysis, however, showed that EEG (p≤.02)  and seizure type (p≤.001) were the best and only 
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significant independent predictors (Table 2), whereas neurological examination did not predict 
significantly the outcome “no response”. We also represented the results of our statistical 
analysis as a mosaic plot, in which the width of each different area is proportional to the 
number of observed cases in each cell (Figure 4). 
After the exclusion of neonates with NSE, we found a complete response in 57 subjects (62.6%), a 
partial response in 15 (16.5%) and the absence of response in 19 subjects (20.9%), therefore a 
higher response rate than reported in previous studies (33 to 45%),
3, 21, 22
 possibly related to the 
exclusion of NSE cases from our cohort. When considering complete and partial responders 
together, these correspond to 79.1% of patients in our study, which would be comparable to 80% of 
cases with either complete cessation or substantial improvement already reported.
3
 In spite of the 
raising concerns on its potentially neurotoxic effects,
23
 phenobarbital is still the first choice drug in 
neonates with seizures,
24, 25
 due to longer clinical experience and the inclusion in randomized 
controlled trials. 
Factors predicting response to anticonvulsants have been seldom investigated in the neonatal period. 
In the pediatric epilepsy literature, predictors of medical intractability have been identified, among 
the others, in the presence of neuroimaging abnormalities, status epilepticus, mixed seizure types, 
focal slowing and symptomatic etiology.
10
 
In this study, only background EEG activity (p≤.02) and seizure type (p<.001) were confirmed as 
independent predictors of refractoriness. The association between abnormal background EEG and 
lack of response to phenobarbital was already described by Boylan et al.,
26, 27
 even though the small 
sample size did not allow inferential statistical analysis. Furthermore, a tendency for responders to 
show normal or only mildly abnormal EEG background has been reported.
28
 As background EEG 
represents one of the major prognostic factors in the context of NS,
29
 it is likely that its role as a 
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predictor of response to therapy identifies severely affected newborns, as already concluded by 
others.
30 
 
The second predictor of lack of response to phenobarbital was the presence of electrographic-only 
versus one or more electroclinical seizure types. It is still debated whether all NS (electrographic as 
well as electroclinical) should be treated,
31, 32
 even if evidence has been gathered on a correlation 
between electrographic-only seizures and unfavorable neurological outcome.
33
 In a randomized 
controlled study on treatment of NS in full-term newborns with moderate-to-severe hypoxic-
ischemic encephalopathy, a trend towards a shorter seizure duration in the group treated for both 
clinical and subclinical events was found, which was also related to prompter and more appropriate 
administration of anticonvulsants.
34 
Our results suggest a potential need for an intensification of our 
surveillance strategies in high risk newborns, in order to enable clinicians to detect neonatal seizures 
even if subclinical and to correctly estimate their overall burden, because our data seem to confirm a 
detrimental role for electrographic-only seizures. On the other hand, it is important to emphasize 
that we did not analyze whether the presence of electrographic-only seizures identified the most 
severely affected or the younger preterm newborns in our cohort, which might provide an alternative 
explanation to our findings. 
Interestingly, we found that the severity of ultrasound scan findings did not predict refractoriness to 
phenobarbital. This might be partially due to methodological limitations of this technique to fully 
assess a contributory role of brain damage in refractoriness to therapy. Alternatively, our finding 
could be interpreted as suggestive of a stronger contribution of functional changes, reflected by 
moderately or severely abnormal EEG activity, on response to medications. This seems to be further 
supported by the absence of a correlation between etiology and absence of a response to 
phenobarbital in our cohort, although it must be acknowledged that our results might also reflect the 
inclusion of heterogeneous conditions in our third group of etiologies for statistical reasons. This 
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hypothesis would be in agreement with studies in the paediatric age, identifying structural lesions as 
a cause of epilepsy refractoriness.
10
 
In our cohort, we found a low percentage of neonates with transient metabolic derangements, such 
as hypoglycaemia or hypocalcaemia, who readily responded to etiological therapy. Transient 
metabolic derangements as a cause of NS are known to have significantly decreased over the last 
decades.
35
 In this cohort, 54/107 (50.5%) of seizing neonates had a moderately to severely abnormal 
neurological examination at onset and 85/107 (79.4%) had moderate-to-severe cranial ultrasound 
abnormalities, reflecting higher rates of acute symptomatic seizures deriving from intraventricular 
hemorrhage. 
One potential limitation is that plasma levels of phenobarbital were not routinely obtained in all 
patients, since therapeutic decisions were usually necessary before plasma level results could be 
available. Nevertheless, blood concentration of phenobarbital is highly variable in neonates
36  
due to 
its pharmacokinetic properties including the variability of plasma protein binding in newborns limits 
the value of estimates of total concentration. 
In summary, this study reports on the response rate to phenobarbital in newborns with 
electrographically-confirmed NS, excluding neonates with NSE. We identified background EEG 
and the presence of electrographic-only seizures as predictors of refractoriness to phenobarbital 
therapy. 
Our findings suggest that refractoriness to phenobarbital can be predicted on the basis of 
background EEG and seizure type findings. Identification of early predictors of phenobarbital 
refractoriness might represent a useful research field, providing neonatologists and pediatric 
neurologists with early and readily available clinical tools potentially impacting on quick decision-
making. The negative effect of electrographic-only seizures on response to phenobarbital also 
suggests a need for close EEG surveillance of high risk newborns. 
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Tables titles and legends 
Table 1. Clinical, neurophysiological and neuroradiological data and their association with response 
to phenobarbital. 
List of abbreviatons: n: number, %: percentage, CI: confidence interval, GA: gestational age, BW: 
birth weight, g: grams, min: minutes, HIE: hypoxic-ischaemic encephalopathies, h: hours, CrUSS: 
cranial ultrasound scan, EEG: electroencephalogram, CruSS I: normal, CrUss II: mildly abnormal, 
CrUss III: severely abnormal.  
 
Table 2. Predictors of non-responsiveness to phenobarbital. 
List of abbreviations. CI: confidence interval; EEG: elctroencephalogram; EEG I: normal/mildy 
abnormal; seizure type 1: one electroclinical seizure type; seizure type 2: more than one 
electroclinical seizure type; OR: odds ratio.  
 
Figure legends 
Figure 1. Study methods. BW: birth weight; CrUSS: cranial ultrasound scan; EEG: 
electroencephalogram; GA: gestational age; HIE: hypoxic-ischaemic encephalopathy; hrs: hours; 
IVH: intraventricular haemorrhage; NICU: neonatal intensive care unit; NS: neonatal seizures; PB: 
phenobarbital. 
Figure 2. Therapeutical protocol in our Unit at the time of the study. EEG: electroencephalogram; 
IV: intravenous; kg: kilogram; MDZ: midazolam; mg: milligram; min: minute; µg: microgram; NS: 
neonatal seizures; PB: phenobarbital; PHT: phenytoin. 
Figure 3. Distribution of different electroclinical seizure types in our cohort, divided according to 
response to phenobarbital (complete response, partial response or no response) and gestational age 
(preterm versus full-term newborns). Figure 3A shows the distribution of different electroclinical 
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seizure types in newborns with only one seizure type, figure 3B shows different combinations of 
electroclinical seizures in newborns with more than 1 seizure type. If clonic seizures are 
present, the patient is classified as “prevailing clonic”, while for other seizure types, each 
newborn is classified according to the main seizure type into myoclonic, tonic or subtle. 
Figure 4. The mosaic plot allows to examine the relationship among two or more categorical 
variables. The horizontal bar widths are proportional to the conditional probability associated 
to each categorical variable: response to the phenobarbital (response: white, partial response: 
light gray, no response: dark gray), EEG (normal/mildly abnormal: diagonal pattern, 
moderately/severely abnormal: horizontal pattern) and seizure type (more than one seizure 
type: thin edge, one seizure type: medium edge, electrographic-only: large edge).  
List of abbreviatons: C: clonic, fC: focal clonic, E: electrographic, FT: full-term newborn, M: 
myoclonic, mC: multifocal clonic, Part Resp.: partial responder, PT: preterm newborn, Resp.: 
Responder, S: subtle, T: tonic. 
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a: response cohort; b: partial response cohort; c OR not evaluable 
  Response to phenobarbital, n (%)     
Variables All  
n (%) 
Response Partial 
response 
No 
response 
P Odd Ratio 95%CI p 
Delivery     .5    
Spontaneous 41 (45.5) 24 (58.5) 9 (21.9) 8 (19.5)     
Caesarean 
Section 
50 (55.5) 33 (66) 6 (12) 11 (22)    
GA     .5    
≥37 45 (49.5) 28 (62.2) 9 (20) 8 (17.8)     
30-36 17 (18.7) 10 (58.8) 4 (23.5) 3 (17.7)    
≤29 29 (31.8) 19 (65.5) 2 (6.9) 8 (27.6)   
BW     .3    
≥2500g 48 (52.7) 31 (64.6) 8 (16.6) 9 (1.8)     
1500-2499g 10 (10.9) 5 (50) 4 (40) 1 (10)    
1000-1499g 12 (13.2) 8 (66.6) 2 (16.7) 2 (16.7)   
<1000g 21 (23.1) 13 (61.9) 1 (4.8) 7 (33.3)   
1 min Apgar score     .1    
8-10 36 (39.6) 26 (72.2) 7 (19.5) 3 (8.3)     
4-7 23 25.3) 15 (65.2) 3 (13.1) 5 (21.7)    
0-3 32 (35.2) 16 (50) 5 (15.6) 11 (34.6)   
5 min Apgar score     .43    
8-10 47 (51.6) 31 (66) 8 (17) 8  (17)     
4-7 31 (34.1) 20 (64.5) 3 (9.7) 8 (25.8)    
0-3 13 (14.3) 6 (46.1) 4 (30.8) 3 (23.1)   
10 min Apgar score     .1    
8-10 67 (73.6) 46 (68.7) 10 (14.9) 11 (16.4)     
≤7 24 (26.4) 11 (45.9) 5 (20.8) 8 (33.3)    
Etiology     .7    
HIE 45 (49.4) 29 (64.4) 9 (20) 7 (15.6)     
Cerebral 
Haemorrhage 
21 (23.1) 14 (66.7) 2 (9.5) 5 (23.8)    
Others 25 (27.5) 14 (56) 4 (16) 7 (28)   
Seizure onset     .9    
≤48 h 30 (32.9) 18 (60) 6 (20) 6 (20)     
>48 h 61 (67) 39 (63.9) 9 (14.8) 13 (21.3)    
CrUSS     .3    
I 17 (18.7) 12 (70.6) 4 (23.5) 1 (5.9)     
II 35 (38.5) 24 (68.6) 5 (14.3) 6 (17.1)    
III 39 (42.8) 21 (53.8) 6 (15.4) 12 (30.8)    
Seizure type     .07    
1 type 30 (32.9) 19 (63.3) 3 (10) 8 (26.7) 
 
1   
> 1 type 56 (61.5) 36(64.3) 9 (16.1) 11 (19.6) 
.92a .68-1.23a  
1.27b .58-2.76 b .02b 
Electrographic-only 5 (5.5) 2 (40) 3 (60) 0c    
EEG     .000    
Normal/mildly 
abnormal 
40 (43.9) 32 (80) 7 (17.5) 1 (2.5) 
 
1   
Moderately/seve
rely abnormal 
51 (56.1) 25 (49) 8 (15.7) 18 (35.3) 1.67a 1.29 – 2.17 a .001 
2.84b 1.51-5.36 b .005 
Neurological 
examination 
    .03    
Normal/mildly 
abnormal 
45 (49.4) 30 (66.7) 10 (22.2) 5 (11.1) 
 
1   
Moderately 
abnormal 
32 (35.2) 21 (65.6) 4 (12.5) 7 (21.9) 
1.14a .89-1.4a .002 
1.83b .78-3.34a .005 
Severely 
abnormal 14 (15.4) 6 (42.9) 1 (7.1) 7 (50) 
1.86a 1.1-3.39a .001 
5.3b .82-4.53b .0 
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OR 95% CI p 
Response  
Intercept  
  
.000 
Normal / mildly abnormal EEG  19.14 2.30-159.29 .006 
Seizure: one type .002 .00017-.0022 .000 
Partial 
response 
Intercept 
  
.000 
Normal / mildly abnormal EEG  16.74 1.57-177.82 .02 
Seizure: one type .001 .00039-.0023 .000 
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Figure 1. Study methods. BW: birth weight; CrUSS: cranial ultrasound scan; EEG: electroencephalogram; 
GA: gestational age; HIE: hypoxic-ischaemic encephalopathy; hrs: hours; IVH: intraventricular 
haemorrhage; NICU: neonatal intensive care unit; NS: neonatal seizures; PB: phenobarbital.  
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Figure 2. Therapeutical protocol in our Unit at the time of the study. EEG: electroencephalogram; IV: 
intravenous; kg: kilogram; MDZ: midazolam; mg: milligram; min: minute; µg: microgram; NS: neonatal 
seizures; PB: phenobarbital; PHT: phenytoin.  
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Figure 3. Distribution of different electroclinical seizure types in our cohort, divided according to response to 
phenobarbital (complete response, partial response or no response) and gestational age (preterm versus 
full-term newborns). Figure 3A shows the distribution of different electroclinical seizure types in newborns 
with only one seizure type, figure 3B shows different combinations of electroclinical seizures in newborns 
with more than 1 seizure type. If clonic seizures are present, the patient is classified as “prevailing clonic”, 
while for other seizure types, each newborn is classified according to the main seizure type into myoclonic, 
tonic or subtle.  
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Figure 4. The mosaic plot allows to examine the relationship among two or more categorical variables. The 
horizontal bar widths are proportional to the conditional probability associated to each categorical variable: 
response to the phenobarbital (response: white, partial response: light gray, no response: dark gray), EEG 
(normal/mildly abnormal: diagonal pattern, moderately/severely abnormal: horizontal pattern) and seizure 
type (more than one seizure type: thin edge, one seizure type: medium edge, electrographic-only: large 
edge).  
List of abbreviatons: C: clonic, fC: focal clonic, E: electrographic, FT: full-term newborn, M: myoclonic, mC: 
multifocal clonic, Part Resp.: partial responder, PT: preterm newborn, Resp.: Responder, S: subtle, T: tonic. 
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